Last reviewed · How we verify

Nicotrol

National Institute on Drug Abuse (NIDA) · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Nicotrol is a Small molecule drug developed by National Institute on Drug Abuse (NIDA). It is currently FDA-approved. Also known as: Nicotine Inhaler.

Nicotrol is a transdermal nicotine replacement therapy used to treat nicotine dependence, which is a medically approved way to help people quit smoking or stop chewing tobacco. It works by acting as an agonist on the neuronal acetylcholine receptor, specifically the alpha4/beta2 subtype.

At a glance

Generic nameNicotrol
Also known asNicotine Inhaler
SponsorNational Institute on Drug Abuse (NIDA)
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Nicotrol

What is Nicotrol?

Nicotrol is a Small molecule drug developed by National Institute on Drug Abuse (NIDA).

Who makes Nicotrol?

Nicotrol is developed and marketed by National Institute on Drug Abuse (NIDA) (see full National Institute on Drug Abuse (NIDA) pipeline at /company/national-institute-on-drug-abuse-nida).

Is Nicotrol also known as anything else?

Nicotrol is also known as Nicotine Inhaler.

What development phase is Nicotrol in?

Nicotrol is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing